NCT02530918 - Study of DS-7080a for the Treatment of Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

January 2, 2018

Study Completion Date

January 2, 2018

Conditions

Neovascular Age-Related Macular DegenerationDiabetic Macular Edema

Interventions

DRUG

DS-7080a

1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution

DRUG

Ranibizumab

0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution

Trial Locations (12)

Baltimore

Fort Myers

Omaha

San Antonio

Austin

Abilene

Phoenix

Beverly Hills

Arcadia

Palm Desert

Silverdale

Boston